Understanding Anthracycline Resistance in Breast Cancer
Author Information
Author(s): Pivot X, Asmar L, Buzdar A U, Valero V, Hortobagyi G
Primary Institution: University of Texas MD Anderson Cancer Center
Hypothesis
The study aims to determine the response rates and duration to second- and third-line chemotherapy in patients with anthracycline-resistant breast cancer.
Conclusion
Strictly defined anthracycline resistance is linked to resistance to many other cytotoxic drugs, while broader definitions include more patients with responsive tumors and better prognosis.
Supporting Evidence
- Response rates to second-line chemotherapy were 5% and 7.7% for Groups 1 and 2.
- Response rates to second-line chemotherapy were 21.6% and 15% for Groups 3 and 4.
- The differences in response rates between Groups 1 and 2 and Groups 3 or 4 were significant.
Takeaway
This study looked at how well breast cancer patients respond to treatments after they don't respond to a specific type of drug called anthracycline. It found that some definitions of resistance mean patients might still respond to other treatments.
Methodology
Retrospective analysis of patients with metastatic breast cancer who participated in clinical trials of anthracycline-containing chemotherapy.
Participant Demographics
Patients with metastatic breast cancer from clinical trials at the University of Texas MD Anderson Cancer Center.
Statistical Information
P-Value
0.005 and 0.04
Statistical Significance
p=0.005 and p=0.04
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website